Solara Active Pharma Sciences Limited

Informe acción NSEI:SOLARA

Capitalización de mercado: ₹36.6b

Salud financiera de hoja de balance de Solara Active Pharma Sciences

Salud financiera controles de criterios 3/6

Solara Active Pharma Sciences tiene un patrimonio de los accionistas total de ₹10.9B y una deuda total de ₹8.2B, lo que sitúa su ratio deuda-patrimonio en 75.3%. Sus activos y pasivos totales son ₹22.9B y ₹12.0B respectivamente.

Información clave

75.3%

Ratio deuda-patrimonio

₹8.20b

Deuda

Ratio de cobertura de interesesn/a
Efectivo₹60.70m
Patrimonio₹10.89b
Total pasivo₹12.01b
Activos totales₹22.90b

Actualizaciones recientes sobre salud financiera

Recent updates

The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More

Sep 13
The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More

Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce

Jul 20
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce

Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

Jun 05
Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

May 11
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Apr 19
Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Mar 13
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Feb 23
Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Jan 04
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

May 12
Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Nov 08
Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Sep 30
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Aug 03
Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Jun 19
Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17
Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Dec 21
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (₹7.6B) de SOLARA no cubren sus pasivos a corto plazo (₹10.5B).

Pasivo a largo plazo: Los activos a corto plazo de SOLARA (₹7.6B) superan a sus pasivos a largo plazo (₹1.5B).


Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de SOLARA (74.7%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de SOLARA ha crecido de 58.2% a 75.3% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable SOLARA tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.

Pronóstico de cash runway: SOLARA no es rentable, pero tiene suficiente cash runway para más de 3 años, incluso con un flujo de caja libre positivo que se reduce un 4.7% al año.


Descubre empresas con salud financiera